Observational study suggests that an early one-week treatment at the first sign of viral reactivation may achieve clinical benefits and avoid antiviral toxicity.
Ribavarin, ritonavir, abacavir and lamivudine were the primary triggers.
CSF foscarnet concentrati.ons were very near IC50 and were followed by sharp reductions in viral load.
A new method to assess antiviral activity against DNA viruses has been developed, using automated format and qPCR to measure the accumulation of viral DNA. Of the FDA approved drugs, foscarnet showed the highest selectivity index for HHV-6B.